These findings identify a metabolic vulnerability specific to KRAS/LKB1 co-mutant tumors within the HBP and propose the targeting of PGM3 as a potential therapeutic strategy for this aggressive subtype of NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.